When does 2 plus 2 equal 5? A review of antimicrobial synergy testing

Journal of Clinical Microbiology

Volumn 52, Issue 12, 2014, Pages 4124-4128

  Doern, Christopher D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; MEROPENEM; TIMENTIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL SYNERGY TESTING; BACTERICIDAL ACTIVITY; BURKHOLDERIA CEPACIA; CANDIDA; CHECKERBOARD METHOD; CYSTIC FIBROSIS; DRUG POTENTIATION; ENTEROBACTER CLOACAE; EPSILOMETER TEST; ESCHERICHIA COLI; HUMAN; INTERMETHOD COMPARISON; MEASUREMENT ACCURACY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE COMBINATION BACTERICIDAL ANTIMICROBIAL TESTING; NONHUMAN; PHARMACOLOGICAL PROCEDURES; PREDICTIVE VALUE; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY; REVIEW; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TIME KILL CURVE ASSAY; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PNEUMONIA; PROCEDURES;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PNEUMONIA;

EID: 84910127305     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01121-14     Document Type: Review

References (26)

1. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Rex JH, Pfaller MA. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989. http://dx.doi.org/10.1086/342384.
3. Grasela TH, Jr, Welage LS, Walawander CA, Timm EG, Pelter MA, Poirier TI, Walters JK. 1990. A nationwide survey of antibiotic prescribing patterns and clinical outcomes in patients with bacterial pneumonia. DICP 24:1220-1225.
4. Kollef MH. 2000. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31(Suppl 4):S131-S138. http://dx.doi.org/10.1086/314079.
5. Tamma PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 25:450-470. http://dx.doi.org/10.1128/CMR.05041-11.
6. Saiman L. 2007. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8:249-255. http://dx.doi.org/10.1016/j.prrv.2007.04.006.
7. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Resp. Crit. Care Med. 161:1206-1212. http://dx.doi.org/10.1164/ajrccm.161.4.9907147.
8. Taylor PC, Schoenknecht FD, Sherris JC, Linner EC. 1983. Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors. Antimicrob. Agents Chemother. 23:142-150. http://dx.doi.org/10.1128/AAC.23.1.142.
9. Norden CW, Wentzel H, Keleti E. 1979. Comparison of techniques for measurement of in vitro antibiotic synergism. J. Infect. Dis. 140:629-633. http://dx.doi.org/10.1093/infdis/140.4.629.
10. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. White RL, Burgess DS, Manduru M, Bosso JA. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40:1914-1918.
12. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. 2002. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49:345-351. http://dx.doi.org/10.1093/jac/49.2.345.
13. Cappelletty DM, Rybak MJ. 1996. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:677-683.
14. Matsumura SO, Louie L, Louie M, Simor AE. 1999. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristindalfopristin in combination with other antimicrobial agents. Antimicrob. Agents Chemother. 43:2776-2779.
15. Bonapace CR, White RL, Friedrich LV, Bosso JA. 2000. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn. Microbiol. Infect. Dis. 38:43-50. http://dx.doi.org/10.1016/S0732-8893(00)00163-2.
16. Pankey G, Ashcraft D, Patel N. 2005. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob. Agents Chemother. 49:5166-5168. http://dx.doi.org/10.1128/AAC.49.12.5166-5168.2005.
17. Orhan G, Bayram A, Zer Y, Balci I. 2005. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J. Clin. Microbiol. 43:140-143. http://dx.doi.org/10.1128/JCM.43.1.140-143.2005.
18. Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Haussler S. 2006. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 25:25-30. http://dx.doi.org/10.1007/s10096-005-0076-9.
19. McCaughey G, Gilpin D, Elborn J, Tunney MM. 2013. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Rev. Respir. Med. 7:385-396. http://dx.doi.org/10.1586/17476348.2013.814411.
20. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537. http://dx.doi.org/10.1093/clinids/23.3.532.
21. Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am. J. Resp. Crit. Care Med. 162:2241-2245. http://dx.doi.org/10.1164/ajrccm.162.6.2005018.
22. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. 2004. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168-171. http://dx.doi.org/10.1128/AAC.48.1.168-171.2004.
23. Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. 2007. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 51:1085-1088. http://dx.doi.org/10.1128/AAC.00954-06.
24. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, Bye P, Bell S, Chan F, Rose B, Jeanneret A, Stephenson A, Noseworthy M, Freitag A, Paterson N, Doucette S, Harbour C, Ruel M, MacDonald N. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, doubleblind, controlled clinical trial. Lancet 366:463-471. http://dx.doi.org/10.1016/S0140-6736(05)67060-2.
25. Flume PA, Mogayzel PJ, Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies Committee. 2009. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Resp. Crit. Care Med. 180:802-808. http://dx.doi.org/10.1164/rccm.200812-1845PP.
26. Aaron SD. 2007. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr. Respir. Rev. 8:256-261. http://dx.doi.org/10.1016/j.prrv.2007.04.005.